company featured image
  • Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, oral treatments of cancer and its complications
  • Cantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience

 

READ MORE

pipeline featured image
  • Azeliragon is safe, once-daily oral medication in Phase 2 development that targets glioblastoma, metastatic brain tumors, triple-negative breast cancer, pancreatic cancer, and cancer-related cognitive decline

 

READ MORE

doctor viewing vaccine

March 2023 – Cantex Pharmaceuticals and Baptist Health Miami Cancer Institute announced that the FDA has issued a “Study May Proceed” letter for the Miami Cancer Institute’s investigator initiated clinical trial to assess the safety and effectiveness of azeliragon combined with stereotactic radiosurgery in patients with brain metastases.

 

February 2023 – Cantex Pharmaceuticals announced the FDA issued a “Study May Proceed” letter for the Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy.

 

January 2023 – Cantex Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.

 

READ ALL NEWS

Cantex is developing Azeliragon for the treatment of glioblastoma, brain metastases, breast cancer, pancreatic cancer, and cancer-related cognitive decline.